REG - Iconic Labs PLC - Result of General Meeting

Iconic LabsAnnouncement

27/02/2020 12:55

RNS Number : 3825E
  
Iconic Labs PLC
  
27 February 2020
  
 

Iconic Labs PLC 
27 February 2020
Iconic Labs Plc ("Iconic Labs" or the "Company")
Results of General Meeting
 
Iconic Labs plc (AIM: ICON), a multi-divisional new media and technology business, advises that it held a General Meeting ("GM") earlier today.
 
All resolutions were duly passed on a poll vote. Details of the proxy voting are shown in the table below.
 



Resolutions


Votes For


%


Votes Against


%


Votes Total


Votes Withheld


































1 Authority to sub-divide shares and adopt new articles
(Special Resolution)


153,111,913


88.11


20,665,281


11.89


173,777,194


1,500,000




2 Authority to issue notes and warrants under Deed of Issuance and Financing and Settlement Agreement
(Ordinary Resolution)


153,111,913


88.11


20,665,281


11.89


173,777,194


1,500,000




3. Empowering the directors' to disapply statutory pre-emption rights
(Special Resolution)


152,498,075


87.75


21,279,119


12.25


173,777,194


1,500,000



 
The Company also acknowledges the continual concerns raised by shareholders as to the underlying identity of the holders of its shares and the need for the Company to publish an accurate updated shareholder register.  To that end, the Company issued notices to several shareholders pursuant to its articles requiring disclosure of underlying beneficial holders.  In accordance with the articles, such shares are disenfranchised until the shareholder complies with the notice. 
 
Iconic Labs PLC
 



For information please contact:
 



Damon Heath


Shard Capital Partners LLP


Tel: +44 (0) 20 7186 9950



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ROMUBSURRBUUUAR